2023 AUA preview: Dr. Li on top research in bladder cancer

Video

Roger Li, MD, highlights 4 studies in bladder cancer being presented at the 2023 American Urological Association Annual Meeting.

In this video, Roger Li, MD, discusses 4 studies in bladder cancer being presented at the 2023 American Urological Association Annual Meeting in Chicago, Illinois. Li is a urologic oncologist at Moffitt Cancer Center in Tampa, Florida.

The following abstracts were previewed:

1. LBA02-08 (Milowsky et al): Results from the extended follow-up in patients with muscle-invasive bladder cancer in the CheckMate 274 trial

2. LBA03-08 (Singer et al): Pembrolizumab (pembro) for patients (pts) with high-risk non-muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette-Guerin (BCG): Efficacy and evaluation of subsequent cystectomy from cohort B of the phase 2 KEYNOTE-057 study

3. LBA02-03 (Daneshmand et al): First results from SunRISE-1 in patients with BCG unresponsive high-risk non-muscle-invasive bladder cancer receiving TAR-200 in combination with cetrelimab, TAR-200, or cetrelimab alone

4. PD13-08 (Li et al): CORE1: Phase 2 single arm study of CG0070 combined with pembrolizumab in patients with non muscle invasive bladder cancer unresponsive to bacillus Calmette-Guerin (BCG)

Related Videos
Karine Tawagi, MD
Dr. Jasmeet Kaur in an interview with Urology Times
Dr. Martin Voss in an interview with Urology Times
Dr. Jacqueline Brown in an interview with Urology Times
blurred clinic hallway
Dr. Dalia Kaakour in an interview with red Urology Times backdrop
Dr. Maria Teresa Bourlon in an interview with Urology Times
Dr. David Braun in an interview with Urology Times
Dr. Neeraj Agarwal in an interview with Urology Times
Related Content
Moffitt Study Suggests Improvements Needed for Patient-Reported Outcome Data in Genitourinary Cancer Clinical Studies

Moffitt Study Suggests Improvements Needed for Patient-Reported Outcome Data in Genitourinary Cancer Clinical Studies

February 10th 2024
Article

“Our data showed a considerable gap in reporting patient-reported outcomes and in the quality of design and conduct of patient-reported outcomes-related trial endpoints," said Jad Chahoud, MD, MPH.

blurred photo of a clinic hallway

2023 AUA highlights in benign urology

May 28th 2023
Podcast

Gopal H. Badlani, MD, and Steven A. Kaplan, MD, discuss some of the notable abstracts in benign urology that were presented at the 2023 AUA Annual Meeting.

doctor writing on clipboard in foreground, blurred patient sitting in background

Patients with prostate cancer seek clinical trials earlier vs patients with other cancers

February 1st 2024
Article

Data revealed that 49% of prostate cancer signups in clinical trials were among patients newly diagnosed with cancer, compared with 32% among patients with other solid tumors.

Speaking of Urology: 2023 AUA Highlights

Speaking of Urology: 2023 AUA Highlights

May 12th 2023
Podcast

Adam B. Weiner, MD, and Ruchika Talwar, MD, discuss some of the notable urologic oncology abstracts that were presented at the 2023 AUA meeting.

Human kidney cross section on science background. 3d render. | Image Credit: © Rasi - stock.adobe.com

Subcutaneous nivolumab meets coprimary pharmacokinetic end points for ccRCC

January 30th 2024
Article

Patients in the subcutaneous arm (n = 242) achieved a geometric mean Cavgd28 of 77.373μl/mL (90% CI, 74.555-80.297) compared with 36.875 μl/mL (90% CI, 35.565-38.235) in the IV arm (n = 245), for a geometric mean ratio of 2.098 μl/mL (90% CI, 2.001-2.200).

APL-1202 plus tislelizumab combo shows promise in MIBC

APL-1202 plus tislelizumab combo shows promise in MIBC

January 29th 2024
Article

Overall, the pathological complete response rate among patients who received APL-1202 plus tislelizumab was 39%, compared with 21% among those who received tislelizumab alone.

© 2024 MJH Life Sciences

All rights reserved.